Effect of cilostazol, a new antithrombotic drug, on an experimental model of peripheral circulation insufficiency.

Acute arterial obstruction in hind limb was experimentally induced by intra-arterial injection of sodium laurate saline solution in mongrel dogs, and the inhibitory action of cilostazol (6-[4-(1-cyclohexyl-1H-tetrazol-5-yl)butoxy]- 3,4-dihydro-2(1H)-quinolinone, OPC-13013) on ulcer formation was studied. Cilostazol at oral doses of 10 and 30 mg/kg inhibited ulcer development. Cilostazol inhibited decrease in skin temperature in obstructed hindlimbs in a dose-dependent manner. Cilostazol also inhibited increase of plasma aldolase, creatine phosphokinase and glutamic oxalacetic transaminase activities, presumably due to necrosis of the skeletal muscle.